withdraw guid lt driver
life scienc tool diagnost compani updat
withdraw guidanc provid updat follow signific reduct
custom activ late march due dynam withdraw
guidanc prior organ revenu growth ep note
scope durat impact pandem still remain wide uncertain moreov
disclos expect report organ revenu growth rang
vs prior organ revenu growth estim
lower estim
respect target price anticip
disrupt expect continu tmo earn call april
test updat testament innov effort partial
off-set amongst first sever manufactur receiv fda emerg use
author pcr test march compani util appli
biosystem taqpath assay technolog deliv result within four hour testament
abil rapidli innov respond custom demand expedi manner
encourag innov capabl increment revenu relat
test viru inevit enough off-set associ reduct demand
across tmo broader global oper expect
reiter neutral despit inevit near-term headwind relat
continu view tmo longer term prospect remain larg intact remain highli
lever attract end-market driver also rise biopharma demand particularli
potenti covid-driven fund opportun increas exposur faster-
grow servic market innov geograph expans improv oper
effici said remain neutral junctur note share trade
still well histor averag even despit recent
pullback view near term upsid limit particularli light heighten risk
unknown financi implic relat well deal execut risk
relat pend acquisit see consolid theme continu
dissect qiagen deal
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
mariu zoican univers toronto rotman school manag april
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
thermo fisher lead provid instrument reagent
consum softwar servic custom span
biopharmaceut diagnost academic/government
blue sky scenario predic organ growth
upper end current lt target faster margin expans
thereon support oper leverag ppi initi
share grey sky scenario predic organ growth
lower end current lt target predic slow
fund growth stringent regulatori environ particularli
custom consolid continu compound potenti slower
expect margin expans thereon
 close
mariu zoican univers toronto rotman school manag april
compani mention price
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view
express report
